What's on your mind?

There's both much to know and much to say and we'd like to hear from you; your ideas, your experiences... anything that helps provide perspective on lives that have been impacted by diseases of the central nervous system.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

NEWS

March 21, 2023

Cerevance Announces Presentations at Two Medicinal Chemistry Conferences

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

March 20, 2023

Cerevance Announces Presentations at AD/PD™ 2023 International Conference

  • Positive CVN424 Phase 2 data for Parkinson’s disease to be presented
  • Presentation of NETSseq platform’s ability to reveal novel targets to inform CNS drug development
  • Novel target, CVN417, for the potential treatment of Parkinson’s disease to be disclosed
March 7, 2023

Cerevance Announces Upcoming Presentation at the Alzheimer’s Research UK Conference 2023

Cerevance today announced plans to present at the Alzheimer’s Research UK Conference 2023, held in Aberdeen, Scotland and virtually from March 14-15, 2023.

February 13, 2023

Cerevance Expands Series B Financing with Additional $51 Million

  • Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform
  • CVN424 for Parkinson’s disease will advance to Phase 2 monotherapy study in Q2 2023
  • CVN766 for negative and cognitive symptoms of schizophrenia will advance to Phase 2 study in Q4 2023
  • CVN293 for Amyotrophic Lateral Sclerosis will advance to Phase 1 study in Q3 2023
January 27, 2023

Cerevance Announces Publication in Organic Process Research and Development

Cerevance today announced the publication in Organic Process Research and Development entitled, “Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor”.

January 24, 2023

Cerevance to Participate at the SVB Global Biopharma Conference

Cerevance, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in the upcoming SVB Global Biopharma Conference.

January 9, 2023

Cerevance Announces Positive Topline Data from Phase 1 Clinical Trial of CVN766 for the Potential Use in the Treatment of Schizophrenia

  • CVN766 was well tolerated with no serious adverse events
  • CVN766, which has >1000-fold selectivity for the orexin 1 receptor, was well tolerated and showed no evidence of somnolence
  • Data supports once a day dosing of CVN766 in future studies
December 7, 2022

Cerevance to Present at the RBC Capital Markets Virtual Healthcare Private Company Conference

Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.

November 30, 2022

Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases – Biology and Therapeutics Conference and Publication in Neuropharmacology

  • Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform
  • Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated positive results in human and mouse cell based and electrophysiology assays relevant to neuroinflammation in neurodegenerative disease
  • Data has been concurrently published in the peer-reviewed journal, Neuropharmacology
August 9, 2022

Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease

Cerevance today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.

June 16, 2022

Cerevance to Present During the 5th Annual LSX World Congress USA

Carrie Cook, chief business officer (CBO) of Cerevance, will participate in a fireside chat during the 5th Annual LSX World Congress USA being held in Boston, MA, June 21-22.

June 8, 2022

Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention

Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.